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Background and Aims: To maximize cost/efﬁcay of boceprevir-
based triple therapy (BOC) in patients with HCV-related advanced
ﬁbrosis/cirrhosis.
Methods: ITT SVR12, safety and futility rules value were evaluated
in the multicenter national Italian and Spanish early access Name-
Patient-Program which includes treatment-experienced patients
with HCVG1-related advanced ﬁbrosis/cirrhosis (Metavir F3/4)
treated with BOC in both countries.
Results: 402 patients (mean age 55 years; range 22–75),
316 (78.6%) G1b, 255 (63.4%) F4, 60 (30.9%) with oesophageal
varices, 137 (34.1%) relapsers, 95 (23.6%) partial and 168 (41.8%) null
responders were enrolled. Platelets count <100,000 and albumin
levels <3.5 g/dl were present in 49 (12.2%) and 22 (6.3%) patients,
respectively. 369 (91.8%) received at least 1 dose of BOC. Overall ITT
SVR12 rates and according to prior response to P/R, ﬁbrosis stage
and TW8 HCV-RNA value to P/R/BOC are reported in the table.
At multivariate analysis, the strongest predictors of SVR12 were
TW8 HCV-RNA undetectability (RR, 30.8; 95%CI, 8.7–108.7) and
HCV-RNA detectable but <1000 IU/mL (RR, 9.1; 95%CI, 2.6–31.8)
compared to those with HCV-RNA ≥1000 IU/mL.
Two patients (0.5%) died from multi-organ failure, 13 (3.2%)
developed hepatic decompensation, 41 (10.2%) had severe anemia
(<8.5 g/dl) and 31 (7.7%) required at least one blood transfusion.
Conclusions: In treatment-experienced patients with advanced
ﬁbrosis/cirrhosis, SVR12 attained by BOC was satisfactory. Mortality,
life-threatening adverse events and severe anemia rates were
similar to those reported in other real-practice studies. A TW8
futility rule enables a safely discontinuation of BOC in patients
who are extremely unlikely to achieve SVR, thus optimizing the
effectiveness of treatment in this difﬁcult-to-cure population.
Table: SVR12 by at-entry characteristics and TW8 HCV-RNA
Strata SVR12, N (%) Number Needed to Treat (NNT)
All subjects 172/358
(48.0)
2.1
TW8 HCV-RNA undetectable 112/162
(69.1)
1.4
TW8 HCV-RNA detectable
<1000 IU/ml 50/127 (39.4) 2.5
≥1000 IU/ml 3/43 (7.0) 14.3
Prior relapsers 74/125 (58.2) 1.7
Prior partial responders 41/84 (48.8) 2.0
Prior null responders 56/147 (38.1) 2.6
Metavir F3 73/133 (54.9) 1.8
Metavir F4 99/225
(44.0)
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Background and Aims: Scanty data are available, so far, about the
safety proﬁle of a short-course of interferon-based therapy (IFN)
in cirrhotic patients with severe clinical characteristics. Aim of this
analysis was to retrospectively assess the rate of complications and
death occurred during 12 week IFN in cirrhotic patients enrolled in
the Eltrombopag Enable 1 and 2 cohorts, where only patients with
PLT < 75,000 were included.
Methods: Patients infected by HCVG1 and albumin cut-off value
below of 35 g/dl were considered.
Results: Among 1569 patients included in both studies, 414 (24%)
subjects [281 males, median age 53 (range 27–70), 390 Child–
Pugh A], had less than 35g/dl. During the ﬁrst 84 days period
in the double-blind phase, 3 patients (0.7%) died (due to multi-
organ failure in 2 patients and sepsis in 1 patient) and 44 (10.6%)
developed decompensation or severe infection/sepsis. Post-hoc
analysis of the pooled Enables-studied patients who completed
the entire treatment duration highlights that treatment with
eltrombopag compared to placebo leads to improved SVR even
in this poorest sub-group of patients (SVR 11% vs 8%).
Table: Events in eltrombopag-treated patients
Event Number of patients
Ascites 29
Oesophageal varices bleed 3
Sepsis 3
Encephalopathy 7
Bacterial peritonitis 2
Conclusions: These results suggest that, while waiting for all-oral
regimens, 12 weeks IFN in combination with newer, safer DAAs,
which was reported being associated with high (>80%) cure rates
in HCVG1 patients with cirrhosis might be cautiously proposed
as a life-saving therapy in patients with either low PLT counts or
albumin value. Eltrombopag addition would be a useful platelet
support to increase the number of patients to be treated and to
optimize the on-treatment course dosing of therapy.
S470 Journal of Hepatology 2014 vol. 60 | S361–S522
